AlphaRx Introduces the Next Generation of Topical Pain Relieving Products.Business Editors, Health/Medical Writers RICHMOND HILL, Ontario--(BW HealthWire)--Oct. 1, 2001 AlphaRx Inc. (OTCBB OTCBB See OTC Bulletin Board (OTCBB). :AHRX) announced today that it has completed the development of a series of over-the-counter pain relieving products using the Company's proprietary (BCD (Binary Coded Decimal) The storage of numbers in which each decimal digit is converted into binary and is stored in a single character or byte. For example, a 12-digit number would take 12 bytes. See binary numbers. ) Bioadhesive Colloidal colloidal of the nature of a colloid. colloidal bath a bath containing gelatin, bran, starch or similar substances, to relieve skin irritation and pruritus. Dispersion(TM) Drug Delivery Technology. These new products are deep-penetrating emulsions, scientifically formulated to provide fast, effective and long lasting relief from arthritis, joint and muscle pain. AlphaRx is initially planning to release 3 formulations -- Muscle Pain Formula, Arthritis Formula and Phyto Formula. "We are very excited about the remarkable effectiveness of these new products," said Mr. Michael Lee, President of AlphaRx. "Based on carrageenan car·ra·geen·an or car·ra·geen·in n. Any of a group of closely related colloids derived from several red algae, widely used as a thickening, stabilizing, emulsifying, or suspending agent in pharmaceuticals. studies, anti-inflammatory compounds incorporated in a BCD system suppress induced inflammation up to 4 times more effectively than currently marketed topical NSAID NSAID: see nonsteroidal anti-inflammatory drug. products." "A major benefit of these new products is a reduction in the gastrointestinal side effects that are often associated with the oral administration of NSAID (Non Steroidal Anti-inflammatory Drug) products," Mr. Lee added. NSAIDs are the initial treatment of choice for most kinds of arthritis. Approximately 22 million people are diagnosed annually with rheumatoid arthritis and osteoarthritis osteoarthritis or osteoarthrosis or degenerative joint disease Most common joint disorder, afflicting over 80% of those who reach age 70. It does not involve excessive inflammation and may have no symptoms, especially at first. in the United States. AlphaRx is targeting the 34 million Americans who take over-the-counter pain relievers for their arthritis. AlphaRx has an extensive pain management product pipeline, in different stages of development. Its two prescription topical NSAID's -- 2.0% Indomethacin indomethacin /in·do·meth·a·cin/ (in?do-meth´ah-sin) a nonsteroidal antiinflammatory drug; used in the treatment of various rheumatic and nonrheumatic inflammatory conditions, dysmenorrhea, and vascular headache. and 1.5% Disclofenac -- are scheduled to enter Phase 1 human trials in the near future. No prescription topical NSAID is currently available for sale in the United States. About AlphaRx AlphaRx is engaged in the development of novel formulations of drugs that are insoluble or poorly soluble in water. AlphaRx's broad product pipeline consists of carefully selected, mainly currently marketed drugs which, through the application of its proprietary BCD drug delivery systems, offer improved medical benefits over existing products as well as strong commercial potential. FORWARD LOOKING STATEMENTS: This release contains forward-looking statements within the meaning and pursuant to the Safe Harbor provisions of the Securities Litigation An action brought in court to enforce a particular right. The act or process of bringing a lawsuit in and of itself; a judicial contest; any dispute. When a person begins a civil lawsuit, the person enters into a process called litigation. Reform Act of 1995 and involve risks and uncertainties that may individually or mutually impact the matters herein described, including but not limited to product development and acceptance, manufacturing, competition, regulatory and/or other factors, which are outside the control of the Company. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion